Rationale for RAS mutation-tailored therapies

Steven K. Montalvo, Lianbo Li, Kenneth D. Westover

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies.

Original languageEnglish (US)
Pages (from-to)263-271
Number of pages9
JournalFuture Oncology
Volume13
Issue number3
DOIs
StatePublished - Feb 1 2017

Fingerprint

Mutation
Mutant Proteins
Therapeutics
Patient Selection
Neoplasms

Keywords

  • cancer
  • GTPase
  • isoforms
  • RAS

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rationale for RAS mutation-tailored therapies. / Montalvo, Steven K.; Li, Lianbo; Westover, Kenneth D.

In: Future Oncology, Vol. 13, No. 3, 01.02.2017, p. 263-271.

Research output: Contribution to journalArticle

Montalvo, Steven K. ; Li, Lianbo ; Westover, Kenneth D. / Rationale for RAS mutation-tailored therapies. In: Future Oncology. 2017 ; Vol. 13, No. 3. pp. 263-271.
@article{d6b6a797d0074f4097e837ceab1dcffb,
title = "Rationale for RAS mutation-tailored therapies",
abstract = "RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies.",
keywords = "cancer, GTPase, isoforms, RAS",
author = "Montalvo, {Steven K.} and Lianbo Li and Westover, {Kenneth D.}",
year = "2017",
month = "2",
day = "1",
doi = "10.2217/fon-2016-0363",
language = "English (US)",
volume = "13",
pages = "263--271",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Rationale for RAS mutation-tailored therapies

AU - Montalvo, Steven K.

AU - Li, Lianbo

AU - Westover, Kenneth D.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies.

AB - RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies.

KW - cancer

KW - GTPase

KW - isoforms

KW - RAS

UR - http://www.scopus.com/inward/record.url?scp=85009471707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009471707&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0363

DO - 10.2217/fon-2016-0363

M3 - Article

C2 - 27728979

AN - SCOPUS:85009471707

VL - 13

SP - 263

EP - 271

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -